BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38301967)

  • 21. Proteasome inhibitors restore the STAT1 pathway and enhance the expression of MHC class I on human colon cancer cells.
    Liang YH; Chen KH; Tsai JH; Cheng YM; Lee CC; Kao CH; Chan KY; Chen YT; Hsu WL; Yeh KH
    J Biomed Sci; 2021 Nov; 28(1):75. PubMed ID: 34758826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon regulatory factor element and interferon regulatory factor 1 in the induction of major histocompatibility complex class I genes in neural cells.
    Massa PT; Wu H
    J Interferon Cytokine Res; 1995 Sep; 15(9):799-810. PubMed ID: 8536108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
    Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes.
    Zhou F; Chen J; Zhao KN
    J Gen Virol; 2013 Nov; 94(Pt 11):2504-2514. PubMed ID: 23956301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
    Goodwin R; Ding K; Seymour L; LeMaître A; Arnold A; Shepherd FA; Dediu M; Ciuleanu T; Fenton D; Zukin M; Walde D; Laberge F; Vincent M; Ellis PM; Laurie SA;
    Ann Oncol; 2010 Nov; 21(11):2220-2226. PubMed ID: 20427348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon regulatory factor-1 is required for interferon-gamma-induced MHC class I genes in astrocytes.
    Jarosinski KW; Massa PT
    J Neuroimmunol; 2002 Jan; 122(1-2):74-84. PubMed ID: 11777545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
    Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK
    Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII.
    Nikodemova M; Watters JJ; Jackson SJ; Yang SK; Duncan ID
    J Biol Chem; 2007 May; 282(20):15208-16. PubMed ID: 17395590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evodiamine suppresses non-small cell lung cancer by elevating CD8
    Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
    J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The induction of class I and II major histocompatibility complex by allogeneic stimulation is dependent on the transcription factor interferon regulatory factor 1 (IRF-1): observations in IRF-1 knockout mice.
    Hobart M; Ramassar V; Goes N; Urmson J; Halloran PF
    Transplantation; 1996 Dec; 62(12):1895-901. PubMed ID: 8990383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 35. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
    Smithy JW; Moore LM; Pelekanou V; Rehman J; Gaule P; Wong PF; Neumeister VM; Sznol M; Kluger HM; Rimm DL
    J Immunother Cancer; 2017; 5():25. PubMed ID: 28331615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
    Bar J; Ding K; Zhao H; Han L; Laurie SA; Seymour L; Addison CL; Shepherd FA; Goss GD; Dimitroulakos J; Bradbury PA
    Clin Lung Cancer; 2015 Nov; 16(6):e189-201. PubMed ID: 26081815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Shepherd FA; Laurie S; Gauthier I; Leighl N; Chen E; Feld R; Powers J; Seymour L
    Eur J Cancer; 2009 Mar; 45(5):782-8. PubMed ID: 19091548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
    Yoshino H; Sato Y; Nakano M
    Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes.
    Penninger JM; Sirard C; Mittrücker HW; Chidgey A; Kozieradzki I; Nghiem M; Hakem A; Kimura T; Timms E; Boyd R; Taniguchi T; Matsuyama T; Mak TW
    Immunity; 1997 Aug; 7(2):243-54. PubMed ID: 9285409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.